

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/789,303
				Filing Date	February 26, 2004
				First Named Inventor	Kelly Reed Clark et al.
				Art Unit	1653-1633
				Examiner Name	M. Burkhardt
Sheet	1	of	2	Attorney Docket Number	28335/40012

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
MS		5,622,856	04-22-1997	Natsoulis	
		5,658,776	08-19-1997	Flotte et al.	
		5,658,785	08-19-1997	Johnson	
		5,837,484	11-17-1998	Trempe et al.	
		6,258,595	07-10-2001	Gao et al.	
		6,365,403	04-02-2002	Natsoulis et al.	
		6,475,769	11-05-2002	Wilson et al.	
MB		6,541,258	04-01-2003	Allen et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
MB		WO99/41399	08-19-1999	Wadsworth	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
MB		Aitken et al., <i>Hum Gene Therapy</i> , "A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease", 12:1907-1916 (2001)			
		Carter et al., AAV Vectors for Gene Therapy, in <i>Gene and Cell Therapy : Therapeutic Mechanisms and Strategies</i> , Second Edition (Ed. N. Templeton-Smith), pp. 71-101, Marcel Dekker, New York, 2004			
		Clark et al., <i>Hum Gene Therapy</i> , "Cell Lines for the Production of Recombinant Adeno-Associated Virus", 6:1329-1341 (1995)			
		Clark et al., <i>Gene Therapy</i> , "A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors", 3:1124-1132 (1996)			
		Clark et al., <i>Hum Gene Therapy</i> , "Recombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle", 8(6):659-669 (1997)			
		Clark et al., <i>Hum Gene Therapy</i> , "Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses", 10(6):1031-1039 (1999)			
		Fan and Dong, <i>Human Gene Therapy</i> , "Replication of rep-cap Genes Is Essential for the High-Efficiency Production of Recombinant AAV", 8:87-98 (1997)			
		Gao et al., <i>Molecular Therapy</i> , "Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap", 5(5):644-649 (2002).			
MB		Graham and Prevec, <i>Mol. Biotechnol.</i> , "Methods for Construction of Adenovirus Vectors".			


Examiner Signature	<i>MB</i>	Date Considered	3-28-06
--------------------	-----------	-----------------	---------

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/789,303
				Filing Date	February 26, 2004
				First Named Inventor	Kelly Reed Clark et al.
				Art Unit	1653-1633
				Examiner Name	M. Burkhart
Sheet	2	of	2	Attorney Docket Number	28335/40012

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3-28-06
--------------------	---	-----------------	---------